PMID- 38537582
OWN - NLM
STAT- MEDLINE
DCOM- 20240430
LR  - 20240430
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 174
DP  - 2024 May
TI  - Oxymatrine alleviates high-fat diet/streptozotocin-induced non-alcoholic fatty 
      liver disease in C57BL/6 J mice by modulating oxidative stress, inflammation and 
      fibrosis.
PG  - 116491
LID - S0753-3322(24)00375-5 [pii]
LID - 10.1016/j.biopha.2024.116491 [doi]
AB  - Non-alcoholic fatty liver disease (NAFLD) represents a complex complication of 
      type 2 diabetes mellitus (T2DM). Oxymatrine (OMT) is an alkaloid extracted from 
      Sophora flavescens with broad pharmacological effects. However, there is 
      currently a lack of research on OMT in the field of NAFLD. The present study 
      aimed to explore the effects and underlying mechanisms of oxymatrine in treating 
      T2DM with NAFLD. The T2DM mice model was induced by high-fat diet (HFD) combined 
      with streptozotocin (STZ) injection in male C57BL/6 J mice. Animals were randomly 
      divided into four groups (n = 8): Control group, DC group, OMT-L group (45 mg/kg 
      i.g.), and OMT-H group (90 mg/kg, i.g.). The drug was administered once a day for 
      8 weeks. In addition, HepG2 hepatocytes were incubated with palmitic acid (PA) to 
      establish a fatty liver cell model. Treated with OMT, the body weight and fasting 
      blood glucose (FBG) of DC mice were reduced and the liver organ coefficient was 
      significantly optimized. Meanwhile, OMT markedly enhanced the activities of key 
      antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), and 
      glutathione peroxidase (GSH-Px), and also reduced malondialdehyde (MDA) levels. 
      These biochemical alterations were accompanied by noticeable improvements in 
      liver histopathology. Furthermore, OMT down-regulated the expression of NOD-like 
      receptor protein 3 (NLRP3), interleukin-1beta (IL-1beta), transforming growth factor-beta1 
      (TGF-beta1) and collagen I significantly, highlighting its potential in modulating 
      inflammatory and fibrotic pathways. In conclusion, OMT improved liver impairment 
      effectively in diabetic mice by suppressing oxidative stress, inflammation and 
      fibrosis. These results suggest that OMT may represent a novel therapy for NAFLD 
      with diabetes.
CI  - Copyright (c) 2024 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Lou, Di
AU  - Lou D
AD  - Institution of Pharmacology, College of Pharmaceutical Sciences, Zhejiang 
      University of Technology, Hangzhou, Zhejiang 310014, China.
FAU - Fang, Qing
AU  - Fang Q
AD  - Institution of Pharmacology, College of Pharmaceutical Sciences, Zhejiang 
      University of Technology, Hangzhou, Zhejiang 310014, China.
FAU - He, Yinghao
AU  - He Y
AD  - Institution of Pharmacology, College of Pharmaceutical Sciences, Zhejiang 
      University of Technology, Hangzhou, Zhejiang 310014, China.
FAU - Ma, Ruyu
AU  - Ma R
AD  - Institution of Pharmacology, College of Pharmaceutical Sciences, Zhejiang 
      University of Technology, Hangzhou, Zhejiang 310014, China.
FAU - Wang, Xinyan
AU  - Wang X
AD  - Institution of Pharmacology, College of Pharmaceutical Sciences, Zhejiang 
      University of Technology, Hangzhou, Zhejiang 310014, China.
FAU - Li, Hanbing
AU  - Li H
AD  - Institution of Pharmacology, College of Pharmaceutical Sciences, Zhejiang 
      University of Technology, Hangzhou, Zhejiang 310014, China. Electronic address: 
      hanbing.li@163.com.
FAU - Qi, Minyou
AU  - Qi M
AD  - Institution of Pharmacology, College of Pharmaceutical Sciences, Zhejiang 
      University of Technology, Hangzhou, Zhejiang 310014, China. Electronic address: 
      qiminyou@163.com.
LA  - eng
PT  - Journal Article
DEP - 20240326
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 85U4C366QS (oxymatrine)
RN  - 0 (Quinolizines)
RN  - 0 (Alkaloids)
RN  - 5W494URQ81 (Streptozocin)
RN  - 0 (Blood Glucose)
RN  - 0 (Matrines)
SB  - IM
MH  - Animals
MH  - *Non-alcoholic Fatty Liver Disease/drug therapy/pathology/metabolism
MH  - *Quinolizines/pharmacology
MH  - *Alkaloids/pharmacology
MH  - *Diet, High-Fat/adverse effects
MH  - *Oxidative Stress/drug effects
MH  - Male
MH  - *Mice, Inbred C57BL
MH  - Humans
MH  - *Streptozocin
MH  - Mice
MH  - Hep G2 Cells
MH  - Diabetes Mellitus, Experimental/drug therapy/complications
MH  - Inflammation/drug therapy/pathology
MH  - Liver Cirrhosis/drug therapy/chemically induced/metabolism/pathology
MH  - Liver/drug effects/pathology/metabolism
MH  - Diabetes Mellitus, Type 2/drug therapy/complications
MH  - Blood Glucose/drug effects/metabolism
MH  - *Matrines
OTO - NOTNLM
OT  - Fibrosis
OT  - Inflammation
OT  - Non-alcoholic fatty liver disease
OT  - Oxidative Stress
OT  - Oxymatrine
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/03/28 00:44
MHDA- 2024/04/30 15:55
CRDT- 2024/03/27 19:20
PHST- 2024/01/24 00:00 [received]
PHST- 2024/03/12 00:00 [revised]
PHST- 2024/03/19 00:00 [accepted]
PHST- 2024/04/30 15:55 [medline]
PHST- 2024/03/28 00:44 [pubmed]
PHST- 2024/03/27 19:20 [entrez]
AID - S0753-3322(24)00375-5 [pii]
AID - 10.1016/j.biopha.2024.116491 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2024 May;174:116491. doi: 10.1016/j.biopha.2024.116491. Epub 
      2024 Mar 26.